Abstract：Objective: To explore the clinical effect and feasibility of anti-tuberculosis and anti-tumor concurrent treatment of pulmonary tuberculosis complicated with lung cancer. Methods: A retrospective analysis of clinical data was carried out in 84 patients with pulmonary tuberculosis complicated with lung cancer admitted to our hospital from March 2010 to June 2015, they were divided into single anti-tuberculosis group (single group for short, n=28), anti-tuberculosis and anti-tumor intermittent treatment group (intermittent group for short, n=26), anti-tuberculosis and anti-tumor concurrent treatment group (concurrent group for short, n=30) according to different treatment modalities, intervention effects of different treatment modalities on pulmonary tuberculosis and lung cancer were compared, flow cytometry was used to determine changes of CD3+, CD4+, CD8+ lymphocytes subsets levels changes before and after the intervention, adverse drug reactions in all groups were recorded, lung cancer quality of life rating form (FACT-L) was used to evaluate improvement of survival treatment of patients before and after the intervention. Results: ①efficacy of anti-tuberculosis in the three group was similar, there was no significant difference (P>0.05); ②there was no significant difference in overall remission rate of anti-tumor in single group and intermittent group (P>0.05), overall remission rate of concurrent group was higher than single group and intermittent group (P>0.05); ③before the treatment, there was no significant difference in lymphocytes subsets indexes in the three groups (P>0.05), after the treatment, CD3+, CD4+, CD8+ of intermittent group and concurrent group were significantly increased compared with the same group before the treatment and single group after the treatment (P<0.05), rising range of all indexes of concurrent group were significantly higher than intermittent group (P<0.05); ④there was no significant difference in quality of life scores before the treatment (P>0.05), 3 and 6 months after the treatment, scores of three groups were significantly increased (P<0.05), rising range of intermittent group was significantly higher than single group (P<0.05), rising range of concurrent group was significantly higher than intermittent group (P<0.05); ⑤gastrointestinal reactions and arrest of bone marrow were mainly adverse reactions of three groups, there was no significant difference in adverse reaction rate (P>0.05). Conclusion: Anti-tuberculosis and anti-tumor concurrent treatment of pulmonary tuberculosis complicated with lung cancer can optimize anti-tumor effect, improve immune function of patients, improve quality of life of patients, and does not increase adverse reaction rate, is safe and feasible.
任建华, 李宁秀, 余豪杰, 蒲华星, 何黎. 抗结核抗肿瘤同期治疗肺结核合并肺癌的效果及可行性分析[J]. 河北医学, 2017, 23(7): 1217-1220.
REN Jianhua, LI Ningxiu, et al. Analysis on the Effect and Feasibility of Anti-tuberculosis and Anti-tumor Concurrent Treatment of Pulmonary Tuberculosis Complicated with Lung Cancer. HeBei Med, 2017, 23(7): 1217-1220.
2017, Vol. 23 
冀公网安备13080202000677号